帕累托改进:我国医保战略性购买的践行路径  

Pareto Improvement:the Practice Path of Strategic Purchase of Medical Insurance in China

作　　者：李毅仁 路云[1] 卢钰琼 常峰[1] LI Yi-ren;LU Yun;LU Yu-qiong;CHANGFeng(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing Jiangsu 211198,China)

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《卫生经济研究》2020年第10期8-11,共4页

基　　金：国家医疗保障局医药价格和招标采购司委托项目“‘十三五’中期药品和高值医用耗材集中采购工作评估项目”。

摘　　要：基于“4+7”集中采购、医保目录准入谈判、抗癌药专项采购等新兴药品购买策略的经济学原理,分析利用帕累托改进等理论指导制定我国医保药品购买战略,采用建立利益代替和激励机制、制定差别化采购战略、配套相应保障政策等措施,促进我国医保战略性购买的长远发展。Based on the economic principles of emerging drug purchase strategies such as"4+7"centralized procurement,medical insurance catalogue access negotiation,and special purchase of anticancer drugs.And guide the formulation of China's medical insurance drug purchase strategy by using Pareto improvement and other theories.Using measures such as establishing benefit substitution and incentive mechanisms,formulating differential procurement strategies and supporting corresponding security policies,and try to promote the long-term development of China's health insurance strategic purchase.

关 键 词：帕累托改进 战略性购买 带量采购 谈判采购 

分 类 号：F840.684[经济管理—保险]